AP NEWS

Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference

September 25, 2018

PRINCETON, N.J.--(BUSINESS WIRE)--Sep 25, 2018--Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Monday, October 1, 2018 at 9:30 a.m. Eastern time. The conference will be held October 1-3, 2018 at the InterContinental New York Barclay Hotel.

Mr. Berlin’s presentation will be webcast live and available for replay in the Investors section of the Company’s website at www.ir.advaxis.com.

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary  Lm -based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes ( Lm ) bioengineered to secrete antigen/adjuvant fusion proteins. These  Lm -based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, personalized neoantigen-directed immunotherapy, off-the-shelf, hotspot/cancer antigens neoantigen-directed immunotherapy and prostate cancer.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005182/en/

CONTACT: Investors:

LHA Investor Relations

Miriam Weber Miller, 212-838-3777

mmiller@lhai.com

or

Advaxis, Inc.

Ranya Dajani, 609-250-7559

dajani@advaxis.com

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Advaxis, Inc.

Copyright Business Wire 2018.

PUB: 09/25/2018 08:00 AM/DISC: 09/25/2018 08:01 AM

http://www.businesswire.com/news/home/20180925005182/en

AP RADIO
Update hourly